Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
996
million yenWording
Conditional
How definitive the wording is.Contents of this document
Earnings presentationSecond quarter of the fiscal year ending January 20275 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales0 million yen
Operating profit-1,909 million yen
Ordinary income-1,730 million yen
Net income-1,791 million yen
Full-year earnings forecast
Business profitability
396 million yen
Operating Costs
5,625 million yen
Research and development costs
4,110 million yen
Other
1,515 million yen
Operating profit
-5,229 million yen
Ordinary income
-5,074 million yen
Net income
-5,133 million yen
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Loss was lower than initially forecastBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
R&D expense forecast variance
-812 million yen
Other forecast variance
-184 million yen
Operating expense forecast variance
-996 million yen
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
US interest rates
159.14 yen
New initiatives
- Establishing the domestic launch and commercialization structure for アクーゴ®
- Upstream processes changed from Minaris's US plant to Japan following the plant's closure
- Trial manufacturing agreement with JCR Pharmaceuticals Co., Ltd. aimed at commercial manufacturing of アクーゴ®
- Promotion of smart regional healthcare coordination
Key KPIsA metric the company considers important as a management benchmark.
Drug pricing
72,716,528 yen
Number of sites ready for rollout
8 Facility
Expected first dosing this fiscal year
6 Example
Number of attendees at lectures and other events
1,000 people or more
TBI-01 trial enrollment
9 Example
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Second quarter of the fiscal year ending January 2027 |
| Net Sales | 0 million yen |
| Operating profit | -1,909 million yen |
| Ordinary income | -1,730 million yen |
| Net income | -1,791 million yen |
| Full-year earnings forecast | Business profitability 396 million yen / Operating Costs 5,625 million yen / Research and development costs 4,110 million yen / Other 1,515 million yen / Operating profit -5,229 million yen / Ordinary income -5,074 million yen / Net income -5,133 million yen |
| Self-assessment against the plan | Loss was lower than initially forecast |
| Breakdown of Factors Affecting the Change | R&D expense forecast variance -812 million yen / Other forecast variance -184 million yen / Operating expense forecast variance -996 million yen |
| Key KPIs | Drug pricing 72,716,528 yen / Number of sites ready for rollout 8 Facility / Expected first dosing this fiscal year 6 Example / Number of attendees at lectures and other events 1,000 people or more / TBI-01 trial enrollment 9 Example |
| Assumptions Underlying the Business Outlook | US interest rates 159.14 yen |
| New initiatives | Establishing the domestic launch and commercialization structure for アクーゴ®, Upstream processes changed from Minaris's US plant to Japan following the plant's closure, Trial manufacturing agreement with JCR Pharmaceuticals Co., Ltd. aimed at commercial manufacturing of アクーゴ®, Promotion of smart regional healthcare coordination |
Items this document does not state (19)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because some research and development expenses, mainly manufacturing-related costs for アクーゴ®, were shifted to the second half, the operating loss was ¥996 million lower than initially forecast.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.